Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2021 1
2022 10
2023 5
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

15 results

Results by year

Filters applied: . Clear all
Page 1
Epidemiological, clinical and virological characteristics of four cases of monkeypox support transmission through sexual contact, Italy, May 2022.
Antinori A, Mazzotta V, Vita S, Carletti F, Tacconi D, Lapini LE, D'Abramo A, Cicalini S, Lapa D, Pittalis S, Puro V, Rivano Capparuccia M, Giombini E, Gruber CEM, Garbuglia AR, Marani A, Vairo F, Girardi E, Vaia F, Nicastri E; INMI Monkeypox Group. Antinori A, et al. Euro Surveill. 2022 Jun;27(22):2200421. doi: 10.2807/1560-7917.ES.2022.27.22.2200421. Euro Surveill. 2022. PMID: 35656836 Free PMC article.
Temporal intra-host variability of mpox virus genomes in multiple body tissues.
Rueca M, Tucci FG, Mazzotta V, Gramigna G, Gruber CEM, Fabeni L, Giombini E, Matusali G, Pinnetti C, Mariano A, Butera O, Specchiarello E, Mondi A, Lanini S, Carletti F, Girardi E, Vaia F, Nicastri E, Antinori A, Maggi F. Rueca M, et al. Among authors: gramigna g. J Med Virol. 2023 May;95(5):e28791. doi: 10.1002/jmv.28791. J Med Virol. 2023. PMID: 37226579
Neutralizing antibodies to Omicron after the fourth SARS-CoV-2 mRNA vaccine dose in immunocompromised patients highlight the need of additional boosters.
Rescigno M, Agrati C, Salvarani C, Giannarelli D, Costantini M, Mantovani A, Massafra R, Zinzani PL, Morrone A, Notari S, Matusali G, Pinter GL, Uccelli A, Ciliberto G, Baldanti F, Locatelli F, Silvestris N, Sinno V, Turola E, Lupo-Stanghellini MT, Apolone G; VAX4FRAIL study Group. Rescigno M, et al. Front Immunol. 2023 Jan 27;14:1104124. doi: 10.3389/fimmu.2023.1104124. eCollection 2023. Front Immunol. 2023. PMID: 36776853 Free PMC article.
Persistent B cell memory after SARS-CoV-2 vaccination is functional during breakthrough infections.
Terreri S, Piano Mortari E, Vinci MR, Russo C, Alteri C, Albano C, Colavita F, Gramigna G, Agrati C, Linardos G, Coltella L, Colagrossi L, Deriu G, Ciofi Degli Atti M, Rizzo C, Scarsella M, Brugaletta R, Camisa V, Santoro A, Roscilli G, Pavoni E, Muzi A, Magnavita N, Scutari R, Villani A, Raponi M, Locatelli F, Perno CF, Zaffina S, Carsetti R. Terreri S, et al. Among authors: gramigna g. Cell Host Microbe. 2022 Mar 9;30(3):400-408.e4. doi: 10.1016/j.chom.2022.01.003. Epub 2022 Jan 25. Cell Host Microbe. 2022. PMID: 35134333 Free PMC article.
Immunogenicity to COVID-19 mRNA vaccine third dose in people living with HIV.
Vergori A, Cozzi Lepri A, Cicalini S, Matusali G, Bordoni V, Lanini S, Meschi S, Iannazzo R, Mazzotta V, Colavita F, Mastrorosa I, Cimini E, Mariotti D, De Pascale L, Marani A, Gallì P, Garbuglia A, Castilletti C, Puro V, Agrati C, Girardi E, Vaia F, Antinori A; HIV-VAC study group. Vergori A, et al. Nat Commun. 2022 Aug 22;13(1):4922. doi: 10.1038/s41467-022-32263-7. Nat Commun. 2022. PMID: 35995780 Free PMC article.
Treatment-Emergent Cilgavimab Resistance Was Uncommon in Vaccinated Omicron BA.4/5 Outpatients.
Gruber CEM, Tucci FG, Rueca M, Mazzotta V, Gramigna G, Vergori A, Fabeni L, Berno G, Giombini E, Butera O, Focosi D, Prandi IG, Chillemi G, Nicastri E, Vaia F, Girardi E, Antinori A, Maggi F. Gruber CEM, et al. Among authors: gramigna g. Biomolecules. 2023 Oct 18;13(10):1538. doi: 10.3390/biom13101538. Biomolecules. 2023. PMID: 37892220 Free PMC article.
Humoral and T-Cell Immune Response After 3 Doses of Messenger RNA Severe Acute Respiratory Syndrome Coronavirus 2 Vaccines in Fragile Patients: The Italian VAX4FRAIL Study.
Corradini P, Agrati C, Apolone G, Mantovani A, Giannarelli D, Marasco V, Bordoni V, Sacchi A, Matusali G, Salvarani C, Zinzani PL, Mantegazza R, Tagliavini F, Lupo-Stanghellini MT, Ciceri F, Damian S, Uccelli A, Fenoglio D, Silvestris N, Baldanti F, Piaggio G, Ciliberto G, Morrone A, Locatelli F, Sinno V, Rescigno M, Costantini M; VAX4FRAIL Study Group. Corradini P, et al. Clin Infect Dis. 2023 Feb 8;76(3):e426-e438. doi: 10.1093/cid/ciac404. Clin Infect Dis. 2023. PMID: 35607769 Free PMC article.
Retention of Neutralizing Response against SARS-CoV-2 Omicron Variant in Sputnik V-Vaccinated Individuals.
Lapa D, Grousova DM, Matusali G, Meschi S, Colavita F, Bettini A, Gramigna G, Francalancia M, Garbuglia AR, Girardi E, Puro V, Antinori A, Kovyrshina AV, Dolzhikova IV, Shcheblyakov DV, Tukhvatulin AI, Zubkova OV, Gushchin VA, Logunov DY, Naroditsky BS, Vaia F, Gintsburg AL. Lapa D, et al. Among authors: gramigna g. Vaccines (Basel). 2022 May 21;10(5):817. doi: 10.3390/vaccines10050817. Vaccines (Basel). 2022. PMID: 35632574 Free PMC article.
Safety and immune response kinetics of GRAd-COV2 vaccine: phase 1 clinical trial results.
Agrati C, Castilletti C, Battella S, Cimini E, Matusali G, Sommella A, Sacchi A, Colavita F, Contino AM, Bordoni V, Meschi S, Gramigna G, Barra F, Grassi G, Bordi L, Lapa D, Notari S, Casetti R, Bettini A, Francalancia M, Ciufoli F, Vergori A, Vita S, Gentile M, Raggioli A, Plazzi MM, Bacchieri A, Nicastri E, Antinori A, Milleri S, Lanini S, Colloca S, Girardi E, Camerini R, Ippolito G, Vaia F, Folgori A, Capone S. Agrati C, et al. Among authors: gramigna g. NPJ Vaccines. 2022 Sep 24;7(1):111. doi: 10.1038/s41541-022-00531-8. NPJ Vaccines. 2022. PMID: 36153335 Free PMC article.
15 results